With the new Biograph™ mCT, Siemens brings accurate and reproducible quantification to molecular imaging, giving you the ability to make unprecedented progress in diagnosing and treating our most challenging diseases.
Now you can detect, characterize and monitor the tiniest cancer lesions with reproducible quantification, making cancer treatment more cost effective. Now you can quantify absolute myocardial blood flow, making more accurate treatment decisions, minimizing risk to your patients. Now you can quantify amyloid deposits1 in the brain, making dementia diagnosis possible, slowing disease progression.
1 syngo.PET Amyloid Plaque is intended for use only with approved amyloid radiopharmaceuticals in the country of use. Users should review the drug labeling for approved uses.
| Intelligently reproducible quantification |
| Finest volumetric image accuracy2 |
| Minimum dose and maximum speed |
| Engineered clinical flexibility |
| Industry-best volumetric resolution2 of 87mm³ for high definition in all dimensions |
| ½ dose and 2x scan speed with FAST CARE |
| The only 78 cm large bore PET with a premium CT to grow patient access |
| Accurate and reproducible quantification to quantify amyloid deposits1 in the brain, absolute myocardial blood flow and characterize the smallest cancer lesions. |
| 25% reduction in total patient exam time3 |
| 29% reduction in energy on a per patient basis3 |
| 50% reduction of injected dose or 2x scan speed with ultra HD•PET3 |
| 1 syngo.PET Amyloid Plaque is intended for use only with approved amyloid radiopharmaceuticals in the country of use. Users should review the drug labeling for approved uses. |
| 2 Based upon competitive literature at time of publishing. Data on file |
| 3 Compared to prior product family |
2012-Oct-04 | Author